Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2024

Open Access 01-12-2024 | Cytostatic Therapy | Research

Health-related quality of life and its determinants among cancer patients: evidence from 12,148 patients of Indian database

Authors: Jyoti Dixit, Nidhi Gupta, Amal Kataki, Partha Roy, Nikita Mehra, Lalit Kumar, Ashish Singh, Pankaj Malhotra, Dharna Gupta, Aarti Goyal, Kavitha Rajsekar, Manjunath Nookala Krishnamurthy, Sudeep Gupta, Shankar Prinja

Published in: Health and Quality of Life Outcomes | Issue 1/2024

Login to get access

Abstract

Background

Cancer survivors experience a decrement in health-related quality of life (HRQoL) resulting from the disease as well as adverse effects of therapy. We evaluated the HRQoL of cancer patients, stratified by primary cancer site, stage, treatment response and associated adverse events, along with its determinants.

Methods

Data were collected from 12,148 patients, sampled from seven purposively chosen leading cancer hospitals in India, to elicit HRQoL using the EuroQol questionnaire comprising of 5-dimensions and 5-levels (EQ-5D-5L). Multiple linear regression was used to determine the association between HRQoL and various socio-demographic as well as clinical characteristics.

Results

Majority outpatients (78.4%) and inpatients (81.2%) had solid cancers. The disease was found to be more prevalent among outpatients (37.5%) and inpatients (40.5%) aged 45–60 years and females (49.3–58.3%). Most patients were found to be in stage III (40–40.6%) or stage IV (29.4–37.3%) at the time of recruitment. The mean EQ-5D-5 L utility score was significantly higher among outpatients [0.630 (95% CI: 0.623, 0.637)] as compared to inpatients [0.553 (95% CI: 0.539, 0.567)]. The HRQoL decreased with advancing cancer stage among both inpatients and outpatients, respectively [stage IV: (0.516 & 0.557); stage III (0.609 & 0.689); stage II (0.677 & 0.713); stage I (0.638 & 0.748), p value < 0.001]. The outpatients on hormone therapy (B = 0.076) showed significantly better HRQoL in comparison to patients on chemotherapy. However, palliative care (B=-0.137) and surgery (B=-0.110) were found to be associated with significantly with poorer HRQoL paralleled to chemotherapy. The utility scores among outpatients ranged from 0.305 (bone cancer) to 0.782 (Leukemia). Among hospitalized cases, the utility score was lowest for multiple myeloma (0.255) and highest for testicular cancer (0.771).

Conclusion

Older age, lower educational status, chemotherapy, palliative care and surgery, advanced cancer stage and progressive disease were associated with poor HRQoL. Our study findings will be useful in optimising patient care, formulating individualized treatment plan, improving compliance and follow-up.
Literature
1.
Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029–30.CrossRefPubMed
2.
3.
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–53.CrossRefPubMed
4.
5.
Mallath MK, Taylor DG, Badwe RA, Rath GK, Shanta V, Pramesh CS, Digumarti R, Sebastian P, Borthakur BB, Kalwar A, Kapoor S. The growing burden of cancer in India: epidemiology and social context. Lancet Oncol. 2014;15(6):e205–12.CrossRefPubMed
6.
Gupta A, Shridhar K, Dhillon PK. A review of breast cancer awareness among women in India: Cancer literate or awareness deficit? Eur J Cancer. 2015;51(14):2058–66.CrossRefPubMedPubMedCentral
7.
Tripathi N, Kadam YR, Dhobale RV, Gore AD. Barriers for early detection of cancer amongst Indian rural women. South Asian Journal of Cancer. 2014;3(02):122–7.CrossRefPubMedPubMedCentral
8.
Nyblade L, Stockton M, Travasso S, Krishnan S. A qualitative exploration of cervical and breast cancer stigma in Karnataka, India. BMC Womens Health. 2017;17(1):1–5.CrossRef
9.
Palat G, Stenlander C, Jacob J, Sinha S, Rapelli V, Wiebe T, Brun E, Segerlantz M. Specialized palliative care and the quality of life for hospitalized cancer patients at a low-resource hospital in India. Indian J Palliat Care. 2018;24(3):289.PubMedPubMedCentral
10.
Pramesh CS, Badwe RA, Borthakur BB, Chandra M, Raj EH, Kannan T, Kalwar A, Kapoor S, Malhotra H, Nayak S, Rath GK. Delivery of affordable and equitable cancer care in India. Lancet Oncol. 2014;15(6):e223–33.CrossRefPubMed
11.
Rajpal S, Kumar A, Joe W. Economic burden of cancer in India: evidence from cross-sectional nationally representative household survey, 2014. PLoS ONE. 2018;13(2):e0193320.CrossRefPubMedPubMedCentral
12.
13.
Hebert JR, Ghumare SS, Gupta PC. Stage at diagnosis and relative differences in breast and prostate cancer incidence in India: comparison with the United States. Asian Pac J Cancer Prev. 2006;7(4):547.PubMed
14.
Pakseresht S, Ingle GK, Garg S, Sarafraz N. Stage at diagnosis and delay in seeking medical care among women with breast cancer, Delhi, India. Iran Red Crescent Med J. 2014;16(12).
15.
Smyth EN, Shen W, Bowman L, Peterson P, John W, Melemed A, Liepa AM. Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer. Health Qual Life Outcomes. 2016;14(1):1–0.CrossRef
16.
Arboe B, Goerloev JS, Olsen MH, Dalton SO, Nielsen KF, Nielsen SR, Madsen C, de Nielsen R. Nully Brown P. Social outcomes after high dose chemotherapy with autologous stem cell transplant. Blood. 2016;128(22):1193.CrossRef
17.
Wang H, Manca A, Crouch S, Bagguley T, Yu G, Aas E, Howell D, Burton C, Patmore R, Roman E, Smith A. PCN351-HEALTH-STATE UTILITY VALUES IN DIFFUSE LARGE B-CELL LYMPHOMA. Value in Health. 2018;21:74.CrossRef
18.
Kelly JL, Pandya C, Friedberg JW, Mohile SG. Health-related quality of life in older patients following diffuse large B-cell lymphoma (DLBCL) diagnosis. Blood. 2012;120(21):4287.CrossRef
19.
Efficace F, Gaidano G, Lo-Coco F. Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice? Blood the Journal of the American Society of Hematology. 2017;130(7):859–66.
20.
Au HJ, Ringash J, Brundage M, Palmer M, Richardson H, Meyer RM. Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. Expert Rev PharmacoEcon Outcomes Res. 2010;10(2):119–28.CrossRefPubMed
21.
US Department of Health and Human Services FDA Center for Drug Evaluation and Research laurie. burke@ fda. hhs. gov, US Department of Health and Human Services FDA Center for Biologics Evaluation and Research toni. stifano@ fda. hhs. gov, US Department of Health and Human Services FDA Center for Devices. and Radiological Health SXD@ cdrh. fda. gov. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health and Quality of Life Outcomes. 2006;4(1):79.
22.
European Medicine Agency. The use of patient-reported outcome (PRO) measures in oncology studies. Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man.
23.
Kluetz PG, Slagle A, Papadopoulos EJ, Johnson LL, Donoghue M, Kwitkowski VE, Chen WH, Sridhara R, Farrell AT, Keegan P, Kim G. Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms. Clin Cancer Res. 2016;22(7):1553–8.CrossRefPubMed
24.
Basch E, Geoghegan C, Coons SJ, Gnanasakthy A, Slagle AF, Papadopoulos EJ, Kluetz PG. Patient-reported outcomes in cancer drug development and US regulatory review: perspectives from industry, the Food and Drug Administration, and the patient. JAMA Oncol. 2015;1(3):375–9.CrossRefPubMed
25.
Cella D, Webster K, Cashy J, Kutikova L, Burgess MF, Lin BK, Bowman L, Liepa AM, Gauthier JE, Gregory SA, Johnson SA. Development of a measure of Health-Related Quality of Life for Non-hodgkin’s Lymphoma Clinical Research: The Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym).
26.
Brucker PS, Yost K, Cashy J, Webster K, Cella D. General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof. 2005;28(2):192–211.CrossRefPubMed
27.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. JNCI: J Natl Cancer Inst. 1993;85(5):365–76.CrossRefPubMed
28.
Kind P. The EuroQol instrument. An index of health-related quality of life. Quality of life and pharmacoeconomics in clinical trials. 1996.
29.
30.
Pickard AS, Wilke CT, Lin HW, Lloyd A. Health utilities using the EQ-5D in studies of cancer. PharmacoEconomics. 2007;25(5):365–84.CrossRefPubMed
31.
Agarwal SK, Munjal M, Koul R, Agarwal R. Prospective evaluation of the quality of life of oral tongue cancer patients before and after the treatment. Ann Palliat Med. 2014;3(4):238–43.PubMed
32.
Barrios R, Bravo M, Gil-Montoya JA, Martínez-Lara I, García-Medina B, Tsakos G. Oral and general health-related quality of life in patients treated for oral cancer compared to control group. Health Qual Life Outcomes. 2015;13(1):1–8.CrossRef
33.
Hassel AJ, Danner D, Freier K, Hofele C, Becker-Bikowski K, Engel M. Oral health-related quality of life and depression/anxiety in long-term recurrence-free patients after treatment for advanced oral squamous cell cancer. J Cranio-Maxillofacial Surg. 2012;40(4):e99–102.CrossRef
34.
Indrapriyadharshini K, Madankumar PD, Karthikeyan GR. Oral health-related quality of life in patients treated for oral malignancy at Kanchipuram district, India: a cross-sectional study. Indian J Cancer. 2017;54(1):11.CrossRefPubMed
35.
Rogers SN, Semple C, Babb M, Humphris G. Quality of life considerations in head and neck cancer: United Kingdom National Multidisciplinary guidelines. J Laryngology Otology. 2016;130(S2):49–52.CrossRef
36.
Borggreven PA, Verdonck-de Leeuw IM, Muller MJ, Heiligers ML, De Bree R, Aaronson NK, Leemans CR. Quality of life and functional status in patients with cancer of the oral cavity and oropharynx: pretreatment values of a prospective study. Eur Arch Otorhinolaryngol. 2007;264(6):651–7.CrossRefPubMedPubMedCentral
37.
Infante-Cossio P, Torres-Carranza E, Cayuela A, Gutierrez-Perez JL, Gili-Miner M. Quality of life in patients with oral and oropharyngeal cancer. Int J Oral Maxillofac Surg. 2009;38(3):250–5.CrossRefPubMed
38.
Visacri MB, Ferrari GB, Pimentel R, Ambrósio RD, Lima CS, Mazzola PG, Moriel P. Evaluation of the quality of life of patients before treatment of squamous cell carcinoma of the head and neck by means of chemoradiotherapy. Contemp Oncology/Współczesna Onkologia. 2015;19(2):148–53.CrossRefPubMed
39.
Prinja S, Dixit J, Gupta N, Mehra N, Singh A, Krishnamurthy MN, Gupta D, Rajsekar K, Kalaiyarasi JP, Roy PS, Malik PS. Development of national cancer database for cost and quality of life (CaDCQoL) in India: a protocol. BMJ open. 2021;11(7):e048513.CrossRefPubMedPubMedCentral
40.
41.
Ramasubbu SK, Pasricha RK, Nath UK, Rawat VS, Das B. Quality of life and factors affecting it in adult cancer patients undergoing cancer chemotherapy in a tertiary care hospital. Cancer Rep. 2021;4(2):e1312.CrossRef
42.
Jyani G, Sharma A, Prinja S, Kar SS, Trivedi M, Patro BK, Goyal A, Purba FD, Finch AP, Rajsekar K, Raman S. Development of an EQ-5D value set for India using an Extended Design (DEVINE) study: the Indian 5-Level version EQ-5D Value Set. Value in Health. 2022.
43.
Prieto L, Sacristán JA. What is the value of social values? The uselessness of assessing health-related quality of life through preference measures. BMC Med Res Methodol. 2004;4(1):1–9.CrossRef
44.
Rabin R, Charro FD. EQ-SD: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337–43.CrossRefPubMed
45.
Jyani G, Prinja S, Kar SS, Trivedi M, Patro B, Purba F, Pala S, Raman S, Sharma A, Jain S, Kaur M. Valuing health-related quality of life among the Indian population: a protocol for the development of an EQ-5D value set for India using an extended design (DEVINE) study. BMJ open. 2020;10(11):e039517.CrossRefPubMedPubMedCentral
46.
Dhillon PK, Mathur P, Nandakumar A, Fitzmaurice C, Kumar GA, Mehrotra R, Shukla DK, Rath GK, Gupta PC, Swaminathan R, Thakur JS. The burden of cancers and their variations across the States of India: the global burden of Disease Study 1990–2016. Lancet Oncol. 2018;19(10):1289–306.CrossRef
47.
48.
Cdc.gov. CDC - Concept - HRQOL. 2011. [cited 2016 Apr 20]. Available from: https://​www.​cdc.​gov/​hrqol/​concept.​htm HRQoL concepts. Centers for Disease Control and Prevention. 2018 [cited 2022 Aug 7]. Available from: https://​www.​cdc.​gov/​hrqol/​concept.​htm.​
49.
Feeny D, Furlong W, Mulhern RK, Barr RD, Hudson M. A framework for assessing health-related quality of life among children with cancer. Int J Cancer. 1999;83(S12):2–9.CrossRef
50.
Jyani G, Chauhan AS, Rai B, Ghoshal S, Srinivasan R, Prinja S. Health-related quality of life among cervical cancer patients in India. Int J Gynecologic Cancer. 2020;30(12).
51.
Prinja S, Jeyashree K, Rana S, Sharma A, Kumar R. Wealth related inequalities in self reported morbidity: positional objectivity or epidemiological transition? Indian J Med Res. 2015;141(4):438.CrossRefPubMedPubMedCentral
52.
Gupta N, Pandey AK, Dimri K, Jyani G, Goyal A, Prinja S. Health-related quality of life among breast cancer patients in India. Support Care Cancer. 2022; 30(12):9983–9990. Doi10:1007/s00520-022-07395-7.Epub 2022 Oct 12. PMID: 36222977.
53.
Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96(8):604–15.CrossRefPubMed
54.
Metadata
Title
Health-related quality of life and its determinants among cancer patients: evidence from 12,148 patients of Indian database
Authors
Jyoti Dixit
Nidhi Gupta
Amal Kataki
Partha Roy
Nikita Mehra
Lalit Kumar
Ashish Singh
Pankaj Malhotra
Dharna Gupta
Aarti Goyal
Kavitha Rajsekar
Manjunath Nookala Krishnamurthy
Sudeep Gupta
Shankar Prinja
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2024
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-024-02227-0

Other articles of this Issue 1/2024

Health and Quality of Life Outcomes 1/2024 Go to the issue

Research

Health inequity assessment in Brazil: is EQ-5D-3L sensible enough to detect differences among distinct socioeconomic groups?

Research

Mapping Short Warwick and Edinburgh Mental Wellbeing Scale (SWEMWBS) to Recovering Quality of Life (ReQoL) to estimate health utilities

Review

A scoping review to create a framework for the steps in developing condition-specific preference-based instruments de novo or from an existing non-preference-based instrument: use of item response theory or Rasch analysis

Research

Associations of multimorbidity with body pain, sleep duration, and depression among middle-aged and older adults in China

Research

Reliability of the quality of life-aged care consumers (QOL-ACC) and EQ-5D-5L among older people using aged care services at home

Research

Development and quality assessment of the psychometric properties of the Self-Efficacy in Lifestyle Counselling scale (SELC 20 + 20) using Rasch analysis